Abstract
Forty four schizophrenic patients were randomly assigned to receive risperidone in 4-8 mg doses either once daily or twice daily for 8 weeks. An open trial was conducted to determine the efficacy of once daily administration of risperidone as compared to twice daily administration. Assessment were done on Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) scale Eighty two percent of the once daily patients and 79% of the twice daily patients showed a significant treatment response. No significant differences were observed between the two groups in response pattern and adverse effects at the end point. Risperidone given once daily was as effective as twice daily administration.
Keywords: Risperidone, schizophrenia, dose-frequency
Full Text
The Full Text of this article is available as a PDF (170.2 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Campbell M., Palij M. Measurement of side effects including tardive dyskinesia. Psychopharmacol Bull. 1985;21(4):1063–1080. [PubMed] [Google Scholar]
- Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G. W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed] [Google Scholar]
- Kay S. R., Fiszbein A., Opler L. A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261. [DOI] [PubMed] [Google Scholar]
- Marder S. R., Meibach R. C. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994 Jun;151(6):825–835. doi: 10.1176/ajp.151.6.825. [DOI] [PubMed] [Google Scholar]
- Möller H. J., Bäuml J., Ferrero F., Fuger J., Geretsegger C., Kasper S., Kissling W., Schubert H. Risperidone in the treatment of schizophrenia: results of a study of patients from Germany, Austria, and Switzerland. Eur Arch Psychiatry Clin Neurosci. 1997;247(6):291–296. doi: 10.1007/BF02922257. [DOI] [PubMed] [Google Scholar]
- Müller-Spahn F. Risperidone in the treatment of chronic schizophrenic patients: an international double-blind parallel-group study versus haloperidol. The International Risperidone Research Group. Clin Neuropharmacol. 1992;15 (Suppl 1 Pt A):90A–91A. doi: 10.1097/00002826-199201001-00048. [DOI] [PubMed] [Google Scholar]